Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VLX Ventures is a venture capital firm based in Israel, dedicated to drug development and computational biology. The organization focuses on identifying and establishing startups in the biopharma sector, with a seed investment size of $1 million. Their team comprises experienced professionals with leadership roles in various biopharma initiatives.
VLX Ventures primarily invests in biopharma therapeutic ventures that develop drugs for challenging diseases. Their investment strategy includes supporting digital pharma ventures that integrate deep biology with computational biology, facilitating precision medicine and diagnostics. They engage with startups at various stages, from early pre-clinical to advanced Phase 3 clinical studies.
VLX Ventures' portfolio includes companies involved in multiomics, cancer therapies, autism and fertility treatments (IVF), immunotherapy, anti-infective drugs, targeted neutrophilic therapy, cell therapy for cancer, and ophthalmology.
Email admin@vlx.co.il with your deck to pitch VLX Ventures.
VLX Ventures typically leads investment rounds, particularly in the seed stage, where they can provide substantial support to emerging biopharma startups.
VLX Ventures is open to follow-on investments, especially for companies that demonstrate significant progress in their clinical studies and business development.
The specific size of VLX Ventures' current fund is not publicly disclosed, but they are known to invest $1 million at the seed stage.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.